Pharmaceutical Peptides

Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. FDA-approved in 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy, Tesamorelin is one of the most potent GHRH analogs available. It stimulates robust growth hormone release while reducing visceral adipose tissue. As a B2B supplier, we provide pharmaceutical-grade Tesamorelin in lyophilized form with verified purity exceeding 98% by HPLC.

Technical Specifications

Sequencetrans-3-Hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular FormulaC221H366N72O67S
Molecular Weight5135.90 g/mol
Purity≥98% (HPLC)
FormLyophilized powder
Storage-20°C, desiccated
CAS218949-48-5

Application Areas

  • Lipodystrophy research
  • Visceral adipose tissue reduction studies
  • Growth hormone axis investigation
  • Metabolic syndrome research
  • Body composition optimization studies
  • Cognitive function and GHRH signaling research

Published Research on Tesamorelin

Falutz J et al. (2007) demonstrated in The New England Journal of Medicine that Tesamorelin significantly reduces visceral adipose tissue in HIV-infected patients with lipodystrophy.

A pivotal phase 3 trial published in The Journal of Clinical Endocrinology & Metabolism (2010) confirmed Tesamorelin's efficacy and safety profile, leading to FDA approval.

Research in Journal of Clinical Investigation (2021) explored Tesamorelin's effects on hepatic fat reduction and cardiovascular risk markers in non-HIV populations.

Frequently Asked Questions About Tesamorelin

Tesamorelin is a synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification. It potently stimulates pituitary growth hormone release and is FDA-approved (Egrifta) for treating HIV-associated lipodystrophy.

We supply Tesamorelin at ≥98% (HPLC) purity with full Certificate of Analysis. Due to its larger molecular weight, 98% represents pharmaceutical-grade quality for this compound.

While both are GHRH analogs, Tesamorelin has a full 44 amino acid sequence with N-terminal modification providing enhanced potency and longer duration of action compared to Sermorelin's 29 amino acids.

MOQ depends on the quantity and grade required. Contact our sales team for specific pricing and availability.

Store Tesamorelin at -20°C in lyophilized form. After reconstitution with sterile water, store at 2-8°C and use within 14 days. Protect from light.

Related Pharmaceutical Peptides

Request Price List